期刊
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
卷 99, 期 -, 页码 249-260出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2016.01.004
关键词
AL amyloidosis; Immunomodulatory drugs; Thalidomide; Lenalidomide; Pomalidomide
资金
- Moravian-Silesian Region [MSK 02680/2014/RRC, MSK 02692/2014/RRC]
- Ministry of Education, Youth and Sports (Institutional Development Plan of University of Ostrava) [SGS01/LF/2014-2015, SGS02/LF/2014-2015, SGS03/LF/2015-2016]
- IGA of The Ministry of Health [15-29667A]
- MH CZ-DRO-FNOs
Immunoglobulin light chain amyloidosis (AL amyloidosis) is indeed a rare plasma cell disorder, yet the most common of the systemic amyloidoses. The choice of adequate treatment modality is complicated and depends dominantly on the risk stratification of these fragile patients. Immunomodulatory drugs (IMiDs) are currently used in newly diagnosed patients as well as in salvage therapy in relapsed/refractory patients. IMiDs have a pleiotropic effect on malignant cells and the exact mechanism of their action has been described recently. Thalidomide is the most ancient representative, effective but toxic. Lenalidomide seems to be more effective, nevertheless the toxicity remains high, especially in patients with renal insufficiency. Pomalidomide is the newest IMiD used in this indication with a good balance between efficacy and tolerable toxicity and represents the most promising compound. This review is focused on the evaluation of all three representatives of IMiDs and their roles in the treatment of this malignant disorder. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据